Inogen (NASDAQ:INGN – Get Rating) issued its quarterly earnings data on Thursday. The medical technology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.24, Briefing.com reports. The firm had revenue of $103.38 million during the quarter, compared to analyst estimates of $100.64 million. Inogen had a negative return on equity of 3.83% and a negative net margin of 5.64%. The business’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.22 EPS. Inogen updated its Q3 2022 guidance to EPS.
Inogen Trading Down 3.2 %
Shares of INGN stock traded down $0.93 on Friday, reaching $27.71. 193,090 shares of the stock were exchanged, compared to its average volume of 184,513. The business’s 50 day moving average price is $26.28 and its 200 day moving average price is $28.45. The company has a market capitalization of $632.79 million, a price-to-earnings ratio of -31.49 and a beta of 1.02. Inogen has a twelve month low of $22.51 and a twelve month high of $65.83.
Wall Street Analyst Weigh In
INGN has been the topic of several analyst reports. StockNews.com downgraded Inogen from a “hold” rating to a “sell” rating in a research report on Friday, July 8th. Stifel Nicolaus dropped their target price on Inogen from $40.00 to $30.00 in a research report on Monday, May 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $41.00.
Institutional Investors Weigh In On Inogen
Inogen Company Profile
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
- Get a free copy of the StockNews.com research report on Inogen (INGN)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.